Dr Ali McBride Discusses the Role of Biosimilars in Oncology

At the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center and president of ACCC, discussed the role of biosimilars in oncology and how familiar oncologists and their teams are with them.

Related Videos

Related Content

Advertisement

December 20th 2024

FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara

Cameron Santoro

The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

December 19th 2024

Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab

Kyle Munz

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

December 19th 2024

The High Cost of Shortages of Low-Cost Chemotherapy

Interview by Mary Caffrey

December 19th 2024

ICYMI: Highlights From CHEST 2024

Brooke McCormick

The top 5 most-viewed content from CHEST 2024 included expert interviews and coverage on multiple areas of chest medicine.

Related Content

Advertisement

December 20th 2024

FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara

Cameron Santoro

The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

December 19th 2024

Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab

Kyle Munz

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

December 19th 2024

The High Cost of Shortages of Low-Cost Chemotherapy

Interview by Mary Caffrey

December 19th 2024

ICYMI: Highlights From CHEST 2024

Brooke McCormick

The top 5 most-viewed content from CHEST 2024 included expert interviews and coverage on multiple areas of chest medicine.